Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biodesix, Inc. - Common Stock (NQ:BDSX)

6.475 -0.095 (-1.45%)
Streaming Delayed Price Updated: 2:30 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biodesix, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces One-for-Twenty Reverse Stock Split
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Second Quarter 2025 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Participate in Upcoming Investor Conferences
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS
From Biodesix, Inc.
Via GlobeNewswire
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces First Quarter 2025 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
From Biodesix, Inc.
Via GlobeNewswire
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
Grew full-year revenue to an estimated $71.3 million, an increase of 45% 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance 
From Biodesix, Inc.
Via GlobeNewswire
Biodesix Announces Third Quarter 2024 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Participate in Three Investor Conferences in November
From Biodesix, Inc.
Via GlobeNewswire
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
From Biodesix, Inc.
Via Business Wire
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at Two Investor Conferences in September
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Second Quarter 2024 Results and Highlights
From Biodesix, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.